Dupixent (dupilumab) late-breaking phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine. May 21, 2023. Accessed September 26, 2024.

Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation, has shown efficacy and ...